Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
0 hedge funds and large institutions have $0 invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2022 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $61K → $0 (-$61K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$32K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$15K |
| 3 |
PC
PointState Capital
New York
|
-$10K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| – | -$32K | -270,698 | Closed |
|
|
SFM
2
Sphera Funds Management
Tel Aviv,
Israel
| – | -$15K | -129,500 | Closed |
|
|
PC
3
PointState Capital
New York
| – | -$10K | -100,000 | Closed |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$4K | -30,798 | Closed |
|
OTLKW Hedge Fund Activity: Q1 2022 in Review
0 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q1 2022, worth a combined $0 — down 100% from $61K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of OTLKW and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Cormorant Asset Management, exiting entirely with an estimated $32K sold.
- 0 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q1 2022, down from 4 in Q4 2021.
- Funds reported $0 of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q1 2022, down 100% quarter-over-quarter.
- 0 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q1 2022 and 4 closed out, a net change of -4 holders.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q1 2022 was Cormorant Asset Management, an estimated $32K sold.
Based on aggregated 13F filings for Q1 2022.